Clinical Trial Details
| Trial ID: | L6657 |
| Source ID: | NCT01562561 |
| Associated Drug: | Repaglinide |
| Title: | Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: repaglinide|DRUG: insulin NPH |
| Outcome Measures: | Primary: HbA1c (glycosylated haemoglobin), Week 0 (visit 5); week 26 | Secondary: FPG (fasting plasma glucose), Week 0 (visit 5); week 26|7-point blood glucose profile, Week 0 (visit 5); week 26|Hypoglycaemic episodes, Week 0 (visit 5); week 26|Adverse events, Week 0 (Visit 5); week 26 |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 213 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2001-06-01 |
| Completion Date: | 2002-12-20 |
| Results First Posted: | |
| Last Update Posted: | 2017-02-20 |
| Locations: | Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, 16150, Malaysia|Novo Nordisk Investigational Site, Marikina City, 1800, Philippines|Novo Nordisk Investigational Site, Pasig City, 1605, Philippines|Novo Nordisk Investigational Site, Quezon City, 1100, Philippines|Novo Nordisk Investigational Site, Johannesburg, Gauteng, 2193, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, 4001, South Africa|Novo Nordisk Investigational Site, Brits, North West, 0250, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, 7460, South Africa|Novo Nordisk Investigational Site, Alberton, 1449, South Africa|Novo Nordisk Investigational Site, Tainan city, 710, Taiwan |
| URL: | https://clinicaltrials.gov/show/NCT01562561 |
